Data / Form D filings / Xcell Biosciences, Inc.
Xcell Biosciences, Inc.: Form D filings
Xcell Biosciences, Inc., a biotechnology company in San Francisco, CA, filed 3 Form D notices with the SEC between 2017 and 2024. The latest, on December 17, 2024, reports $1.4 million sold of a $3.5 million offering to 5 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 455 Mission Bay Blvd S, Suite 124, San Francisco, CA, 94158
- Phone
- (415) 937-0321
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1697666
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Dec 17, 2024 | New notice | $3,500,000 | $1,400,000 | $2,100,000 | 5 | Dec 6, 2024 | sec.gov |
| Sep 13, 2021 | New notice | $24,999,983 | $15,488,682 | $9,511,301 | 15 | Aug 11, 2021 | sec.gov |
| Feb 23, 2017 | New notice | $11,948,573 | $11,518,571 | $430,002 | 33 | Jan 24, 2017 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Saeid S. Akhtari | Director | |
| James S. Lim | Executive Officer | |
| Kaz S. Ohno | Executive Officer | |
| Brian S. Feth | Executive Officer, Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Dec 16, 2024 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Xcell Biosciences, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.